source
- Lycia Therapeutics raises $318 million in IPO to fund protein degrader programsLycia Therapeutics, a biotech focused on protein-degrading medicines, priced its initial public offering at about $318 million. The proceeds will be used to advance three LYTAC drug candidates, in…
- Few European-approved cancer drugs deliver high clinical benefit, analysis showsA new analysis of European regulator approvals between Jan 2022 and July 2026 finds that most newly approved cancer medicines provide limited clinical benefit. Out of 97 approved indications acros…